(WebFG News) - Japenese biopharmaceutical company Sosei confirmed that, contrary to recent press speculation about a possible offer for inhaler specialist Vectura, it did not intend to make a bid.
Inhaled product formulation, device design and development company Vectura Group announced its preliminary results for the year ended 31 December on Wednesday, with full year reported revenue of £148m, in line with board expectations.
Generic drug-maker Hikma Pharmaceuticals will carry out a clinical trial of its generic version of GlaxoSmithKline's Advair Diskus asthma drug after consultation with the US drug regulator.
Medical inhaler group Vectura said 2017 full year revenue should be in line with expectations, adding that a strong second half delivered closing cash and cash equivalents of around £104m net of £1.4m outflows in respect of the £15m share buyback which started in November.
Vectura Group: RBC upgrades to Sector Perform with a target price of 450p.
Vectura Group announced on Tuesday that its board has approved a share buyback to return up to £15m of capital to shareholders.
Vectura and Hikma Pharmaceuticals hope a dispute resolution process with US drug regulators will their enable their generic version of GlaxoSmithKline's Advair asthma treatment to overcome an outstanding hurdle.
GlaxoSmithKline and Innoviva have published data demonstrating the superiority in improving lung function for patients with chronic obstructive pulmonary disease of their Anoro Ellipta product compared to a rival once-daily long-acting combination therapy, Stiolto Respimat.
Inhaled airways product device and formulation business Vectura Group confirmed on Tuesday that Novartis Pharma had reported third quarter net sales of $101m for 'Ultibro Breezhaler' and $37m for Seebri Breezhaler.
FTSE 250 inhaler maker Vectura said on Thursday that Sunovion, the US licensee of the group's partner Novartis, has launched the twice-daily long acting muscarinic inhibitor Seebri Neohaler in the US.
Genel Energy: Deutsche Bank upgrades to Hold with a target price of 154p.
Ricardo: Berenberg downgrades to Sell with a target price of 680p.
Respiratory drug device specialist Vectura reported a wider first-half loss as its revenues moved towards recurring sources amid fewer milestone payments.
Drug delivery specialist Vectura has noted comments on Thursday morning by Hikma, its partner on the development of a generic version of the Advair Diskus asthma treatment.
Wiltshire-based pharmaceuticals business Vectura Group announced it had signed an exclusive agreement with NASDAQ listed company Dynavax Technologies.
GlaxoSmithKline has submitted its Relvar Ellipta asthma drug to European regulators for approval as a extended once-daily treatment.
FTSE 250 inhaler maker Vectura was due to present positive outcomes of its Phase I clinical study on the VR942 inhaled asthma treatment at the American Thoracic Society's annual conference later on Monday.
After receiving an unfavourable verdict from US drug regulators, Hikma Pharamceuticals and Vectura felt there was a "low likelihood" that their generic version of asthma treatment Advair would be approved this year.
The FTSE 250 was on the front foot on Tuesday, with the index up 0.5% to 19,832.81 just before the close.
Weir Group: JPMorgan upgrades to Outperform with a target price of 2175p.